scholarly journals Determining the Effect of Pterostilbene on Insulin Secretion Using Chemoproteomics

Molecules ◽  
2020 ◽  
Vol 25 (12) ◽  
pp. 2885
Author(s):  
Chiara Cassiano ◽  
Daniela Eletto ◽  
Alessandra Tosco ◽  
Raffaele Riccio ◽  
Maria Chiara Monti ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Pancreatic Beta Cells ◽  
Metabolic Disorders ◽  
Therapeutic Potential ◽  
Pharmacological Profile ◽  
Biological Targets ◽  
Cell Assays ◽  
Potential Applications ◽  
Insulin Dependent

Pterostilbene, the 3,5-dimethoxy derivative of resveratrol, is a well-known polyphenolic compound, mainly found in blueberries, grapevines, and Pterocarpus marsupium heartwood, which has recently attracted a great deal of attention due to its wide bio-pharmacological profile. Moreover, pterostilbene is more lipophilic than resveratrol, with a consequently better bioavailability and a more interesting therapeutic potential. In this work, a chemoproteomic approach, based on affinity chromatography, was applied on pterostilbene in the attempt to identify the biological targets responsible for its bioactivity. On this basis, syntaxins, a group of proteins involved in the formation of SNARE complexes mediating vesicles exocytosis, were selected among the most interesting pterostilbene interactors. In vitro and in cell assays gave evidence of the pterostilbene ability to reduce insulin secretion on glucose-stimulated pancreatic beta cells, opening the way to potential applications of pterostilbene as a supplement in the care of insulin-dependent metabolic disorders.

scholarly journals Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice

2019 ◽  
Vol 12 ◽  
pp. 117955141987545 ◽  
Author(s):  
RA Perry ◽  
SL Craig ◽  
MT Ng ◽  
VA Gault ◽  
PR Flatt ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Pancreatic Beta Cells ◽  
Receptor Activation ◽  
Contributing Factors ◽  
Glucose Lowering ◽  
Incretin Hormone ◽  
Glucose Levels ◽  
First Time ◽  
Gip Receptor

Hypersecretion and alterations in the biological activity of the incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), have been postulated as contributing factors in the development of obesity-related diabetes. However, recent studies also point to weight-reducing effects of GIP receptor activation. Therefore, generating precise experimental tools, such as specific and effective GIP receptor (GIPR) antagonists, is of key significance to better understand GIP physiology. Thus, the primary aim of the current study was to uncover improved GIPR antagonists for use in rodent studies, using human and mouse GIP sequences with N- and C-terminal deletions. Initial in vitro studies revealed that the GIPR agonists, human (h) GIP(1-42), hGIP(1-30) and mouse (m) GIP(1-30), stimulated ( P < 0.01 to P < 0.001) insulin secretion from rat BRIN-BD11 cells. Analysis of insulin secretory effects of the N- and C-terminally cleaved GIP peptides, including hGIP(3-30), mGIP(3-30), h(Pro3)GIP(3-30), hGIP(5-30), hGIP(3-42) and hGIP(5-42), revealed that these peptides did not modulate insulin secretion. More pertinently, only hGIP(3-30), mGIP(3-30) and h(Pro3)GIP(3-30) were able to significantly ( P < 0.01 to P < 0.001) inhibit hGIP(1-42)-stimulated insulin secretion. The human-derived GIPR agonist sequences, hGIP(1-42) and hGIP(1-30), reduced ( P < 0.05) glucose levels in mice following conjoint injection with glucose, but mGIP(1-30) was ineffective. None of the N- and C-terminally cleaved GIP peptides affected glucose homeostasis when injected alone with glucose. However, hGIP(5-30) and mGIP(3-30) significantly ( P < 0.05 to P < 0.01) impaired the glucose-lowering action of hGIP(1-42). Further evaluation of these most effective sequences demonstrated that mGIP(3-30), but not hGIP(5-30), effectively prevented GIP-induced elevations of plasma insulin concentrations. These data highlight, for the first time, that mGIP(3-30) represents an effective molecule to inhibit GIPR activity in mice.

scholarly journals Curcumin as a therapeutic agent: the evidence fromin vitro, animal and human studies

2010 ◽  
Vol 103 (11) ◽  
pp. 1545-1557 ◽  
Author(s):  
Jenny Epstein ◽  
Ian R. Sanderson ◽  
Thomas T. MacDonald
Keyword(s):  
Molecular Mechanisms ◽  
Therapeutic Potential ◽  
Human Subjects ◽  
Complex Molecule ◽  
Dietary Factors ◽  
Major Constituent ◽  
Western World ◽  
Yellow Colour ◽  
Biological Targets

Curcumin is the active ingredient of turmeric. It is widely used as a kitchen spice and food colorant throughout India, Asia and the Western world. Curcumin is a major constituent of curry powder, to which it imparts its characteristic yellow colour. For over 4000 years, curcumin has been used in traditional Asian and African medicine to treat a wide variety of ailments. There is a strong current public interest in naturally occurring plant-based remedies and dietary factors related to health and disease. Curcumin is non-toxic to human subjects at high doses. It is a complex molecule with multiple biological targets and different cellular effects. Recently, its molecular mechanisms of action have been extensively investigated. It has anti-inflammatory, antioxidant and anti-cancer properties. Under some circumstances its effects can be contradictory, with uncertain implications for human treatment. While more studies are warranted to further understand these contradictions, curcumin holds promise as a disease-modifying and chemopreventive agent. We review the evidence for the therapeutic potential of curcumin fromin vitrostudies, animal models and human clinical trials.

scholarly journals Murine macrophages and pancreatic beta cells. Chemotactic properties of insulin and beta-cytostatic action of interleukin 1.

1987 ◽  
Vol 166 (4) ◽  
pp. 1174-1179 ◽  
Author(s):  
E H Leiter
Keyword(s):  
Insulin Secretion ◽  
Pancreatic Beta Cells ◽  
Islet Cells ◽  
Interleukin 1 ◽  
Inhibitory Effect ◽  
Secretory Product ◽  
In Vitro Techniques ◽  
Mouse Pancreatic Islet ◽  
Potential Interactions

This study has used in vitro techniques to investigate the potential interactions between mouse pancreatic islet cells and syngeneic macrophages (M phi). Islets strongly stimulated M phi migration from agarose microdroplets; insulin was the only one of four islet cell hormones tested that was effective individually. Chronic exposure of islet monolayers to recombinant mouse IL-1, an M phi secretory product, was not cytolytic, but inhibited insulin secretion, reduced intracellular insulin content, and produced beta cell-specific degranulation. These effects were unique to IL-1; another monokine, tumor necrosis factor, as well as the lymphokine IL-2, and lymphotoxin were all without effect on insulin secretion or monolayer viability at the concentrations tested. The potential pathological consequences of the chemoattractive action of insulin on M phi, and the inhibitory effect of IL-1 on insulin secretion, are discussed.

scholarly journals Intracellular ATP Signaling Contributes to FAM3A-Induced PDX1 Upregulation in Pancreatic Beta Cells

2021 ◽  
Author(s):  
Han Yan ◽  
Zhenzhen Chen ◽  
Haizeng Zhang ◽  
Weili Yang ◽  
Xiangyang Liu ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Pancreatic Beta Cells ◽  
Mitochondrial Protein ◽  
Extracellular Atp ◽  
Β Cells ◽  
Pancreatic Β Cells ◽  
Intracellular Atp ◽  
Pdx1 Expression ◽  
Ca2 Channels

AbstractFAM3A is a recently identified mitochondrial protein that stimulates pancreatic-duodenal homeobox 1 (PDX1) and insulin expressions by promoting ATP release in islet β cells. In this study, the role of intracellular ATP in FAM3A-induced PDX1 expression in pancreatic β cells was further examined. Acute FAM3A inhibition using siRNA transfection in mouse pancreatic islets significantly reduced PDX1 expression, impaired insulin secretion, and caused glucose intolerance in normal mice. In vitro, FAM3A overexpression elevated both intracellular and extracellular ATP contents and promoted PDX1 expression and insulin secretion. FAM3A-induced increase in cellular calcium (Ca2+) levels, PDX1 expression, and insulin secretion, while these were significantly repressed by inhibitors of P2 receptors or the L-type Ca2+ channels. FAM3A-induced PDX1 expression was abolished by a calmodulin inhibitor. Likewise, FAM3A-induced β-cell proliferation was also inhibited by a P2 receptor inhibitor and an L-type Ca2+ channels inhibitor. Both intracellular and extracellular ATP contributed to FAM3A-induced PDX1 expression, insulin secretion, and proliferation of pancreatic β cells.

scholarly journals Mesenchymal Stem Cells—Potential Applications in Kidney Diseases

2019 ◽  
Vol 20 (10) ◽  
pp. 2462 ◽  
Author(s):  
Benjamin Bochon ◽  
Magdalena Kozubska ◽  
Grzegorz Surygała ◽  
Agnieszka Witkowska ◽  
Roman Kuźniewicz ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Therapeutic Potential ◽  
Kidney Diseases ◽  
Kidney Injury ◽  
Clinical Effects ◽  
Potential Applications ◽  
The Subject ◽  
Subcutaneous Adipose

Mesenchymal stem cells constitute a pool of cells present throughout the lifetime in numerous niches, characteristic of unlimited replication potential and the ability to differentiate into mature cells of mesodermal tissues in vitro. The therapeutic potential of these cells is, however, primarily associated with their capabilities of inhibiting inflammation and initiating tissue regeneration. Owing to these properties, mesenchymal stem cells (derived from the bone marrow, subcutaneous adipose tissue, and increasingly urine) are the subject of research in the settings of kidney diseases in which inflammation plays the key role. The most advanced studies, with the first clinical trials, apply to ischemic acute kidney injury, renal transplantation, lupus and diabetic nephropathies, in which beneficial clinical effects of cells themselves, as well as their culture medium, were observed. The study findings imply that mesenchymal stem cells act predominantly through secreted factors, including, above all, microRNAs contained within extracellular vesicles. Research over the coming years will focus on this secretome as a possible therapeutic agent void of the potential carcinogenicity of the cells.

Glucose responsiveness and acetylcholine sensitivity of pancreatic beta-cells after vagotomy

1984 ◽  
Vol 246 (6) ◽  
pp. R985-R993 ◽  
Author(s):  
L. A. Campfield ◽  
F. J. Smith ◽  
R. E. Eskinazi
Keyword(s):  
Insulin Secretion ◽  
Beta Cells ◽  
Pancreatic Beta Cells ◽  
Acetylcholine Receptors ◽  
Sham Operation ◽  
Neural Input ◽  
Acetylcholine Sensitivity ◽  
Long Evans ◽  
In Vitro Insulin Secretion

The chronic effects of removal of parasympathetic neural input to the pancreas on in vitro insulin secretion were assessed. Groups of Wistar and Long-Evans rats received total subdiaphragmatic vagotomy or sham operation. Four to ten weeks later, after the return of food intake and body weight in the vagotomized groups to values similar to the sham-operated groups, pancreatic islets were isolated and statically incubated with selected concentrations of glucose and acetylcholine. Two experimental protocols were used. In the first experiment, insulin secretion in response to basal (5 mM) glucose was 59 +/- 15 (SE) and 65 +/- 13% greater in islets from the vagotomized Wistar and Long-Evans groups, respectively, than in the corresponding sham groups. The enhancement of insulin secretion by several doses of acetylcholine observed in islets from sham-operated groups was totally absent in islets from both vagotomized strains. In the second experiment, insulin secretion was determined in response to selected glucose concentrations by using islets from Wistar rats. An upward and leftward shift of the dose-response curve was observed in the vagotomized group causing 5 mM to become a stimulatory glucose concentration and increasing the stimulatory potency of 10 mM glucose. These results suggest that interruption of vagal input to pancreatic beta-cells may induce a compensatory increase in responsiveness to glucose and a functional suppression of acetylcholine receptors. These data provide further support for the hypothesis that vagal input plays a functionally important role in the control of insulin secretion and maintenance of acetylcholine sensitivity.

scholarly journals The dynamin-related GTPase Opa1 is required for glucose-stimulated ATP production in pancreatic beta cells

2011 ◽  
Vol 22 (13) ◽  
pp. 2235-2245 ◽  
Author(s):  
Zhongyan Zhang ◽  
Nobunao Wakabayashi ◽  
Junko Wakabayashi ◽  
Yasushi Tamura ◽  
Woo-Jin Song ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Electron Transport ◽  
Beta Cells ◽  
Pancreatic Beta Cells ◽  
Electron Transport Chain ◽  
Chain Complex ◽  
Atp Production ◽  
Transport Chain

Previous studies using in vitro cell culture systems have shown the role of the dynamin-related GTPase Opa1 in apoptosis prevention and mitochondrial DNA (mtDNA) maintenance. However, it remains to be tested whether these functions of Opa1 are physiologically important in vivo in mammals. Here, using the Cre-loxP system, we deleted mouse Opa1 in pancreatic beta cells, in which glucose-stimulated ATP production in mitochondria plays a key role in insulin secretion. Beta cells lacking Opa1 maintained normal copy numbers of mtDNA; however, the amount and activity of electron transport chain complex IV were significantly decreased, leading to impaired glucose-stimulated ATP production and insulin secretion. In addition, in Opa1-null beta cells, cell proliferation was impaired, whereas apoptosis was not promoted. Consequently, mice lacking Opa1 in beta cells develop hyperglycemia. The data suggest that the function of Opa1 in the maintenance of the electron transport chain is physiologically relevant in beta cells.

scholarly journals Tankyrase interacts with the allosteric site of glucokinase and inhibits its glucose-sensing function in the beta cell

2021 ◽  
Author(s):  
Nai-Wen Chi ◽  
Travis Eisemann ◽  
Tsung-Yin J Yeh ◽  
Swati Roy ◽  
Tyler J Chi ◽  
...  
Keyword(s):  
Insulin Secretion ◽  
Beta Cell ◽  
Beta Cells ◽  
Pancreatic Beta Cells ◽  
Glucose Sensor ◽  
Pancreatic Beta Cell ◽  
Glucose Sensing ◽  
Binding Motif ◽  
Allosteric Site

Insulin secretion in the pancreatic beta cell is rate-limited by glucokinase (GCK), the glucose sensor that catalyzes the first step of glucose metabolism. GCK consists of two lobes connected by a flexible hinge that allows the kinase to sample a spectrum of conformations ranging from the active, closed form to several inactive, less-compact forms. Activating GCK mutations can cause hyperinsulinemia and hypoglycemia in infants. A similar phenotype is exhibited in mice deficient in tankyrase (TNKS), prompting us to investigate whether TNKS might modulate the glucose-sensing function of GCK. We found that TNKS colocalizes and directly interacts with GCK. Their interaction is mediated by two ankyrin-repeat clusters (ARC-2 and -5) in TNKS and a tankyrase-binding motif (TBM, aa 63-68) in the GCK hinge. This interaction is conformation sensitive: human GCK variants that cause hyperglycemia (V62M) or hypoglycemia (S64Y) enhance or diminish the interaction respectively, even though they have no impact on TNKS interaction in the context of a GCK peptide (V62M) or a peptide library (S64Y). Moreover, the TNKS-GCK interaction is inhibited by high concentrations of glucose, which are known to stabilize GCK in the active (closed, glucose-avid) conformation. Conversely, glucose phosphorylation by GCK in vitro is inhibited by TNKS. To validate this in vitro inhibitory effect in the MIN6 beta cells, we showed that glucose-stimulated insulin secretion is suppressed upon stabilization of the TNKS protein and conversely is enhanced upon TNKS knockdown. Based on these findings as well as by contrasting with hexokinase-2, we propose that TNKS is a physiological GCK inhibitor in pancreatic beta cells that acts by trapping the kinase in an open (inactive) conformation.

Abstract 393: Pancreatic Beta Cell Export of miR-375 to High-Density Lipoproteins is Inversely Associated With Insulin Secretion

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Leslie R Sedgeman ◽  
Quanhu Sheng ◽  
Yan Guo ◽  
Kasey C Vickers
Keyword(s):  
Insulin Secretion ◽  
Beta Cells ◽  
Pancreatic Beta Cells ◽  
Pancreatic Beta Cell ◽  
High Density ◽  
High Density Lipoproteins ◽  
Mirna Processing ◽  
Chronic Hyperglycemia ◽  
Cholesterol Transporters

microRNAs (miRNAs) are critical regulators of glucose metabolism and contribute to the pathogenesis of Type 2 Diabetes (T2D). Recently, we reported that high-density lipoproteins (HDL) transport and deliver functional miRNAs to recipient cells. Here, we report that miR-375 is decreased on HDL in two models of chronic hyperglycemia -- T2D human subjects and Zucker Diabetic Fatty (ZDF) rats. Since miR-375 expression in the islets is 10X greater than in other organs, we tested whether pancreatic beta cells have the ability to export miR-375 to HDL through in vitro export assays, incubating HDL with INS1 beta cells or primary human islets. Indeed, we found miR-375 to be readily exported to HDL from INS1 cells and primary islets in vitro . To determine if cholesterol transporters contribute to HDL-miR-375 export from beta cells, Abca1, Abcg1 and Scarb1 (SR-BI) were inhibited using siRNAs; however, we found that knockdown of each of these transporters failed to affect the beta cell’s ability to export miR-375 to HDL. Nonetheless, enhancing insulin secretion with tolbutamide resulted in the suppression of HDL-miR-375 export, suggesting that miRNA export and insulin secretion are inversely regulated. To determine the roles of Argonaute (Ago) family proteins in HDL-miRNA export, INS1 cells were transfected with siRNAs against Eif2c1-4 to knockdown Ago1-4. We found HDL-miR-375 export to be suppressed when Ago1, but not Ago2-4, were inhibited, suggesting that miRNA export is downstream of miRNA processing by Ago1. We are currently investigating the relationship between HDL-miR-375 export, insulin secretion, and miRNA processing in pancreatic beta cells to elucidate the mechanism(s) controlling HDL-miR-375 export. Collectively, results suggest that a large fraction of HDL-miRNAs originate from pancreatic beta cells and HDL-miRNAs are exported independent of cholesterol transporters.

Sign in / Sign up

Export Citation Format

Share Document